Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals
Science for just $15 USD. Prolonged prevention of autoimmune diabetes Teplizumab was previously shown in a clinical trial to delay onset of type 1 diabetes (T1D) in high-risk relatives of individuals with T1D. Now, Sims et al. extend the follow-up analysis of this trial by 12 months, finding that efficacy of the initial 2-week treatment course persisted, with an extended time to T1D diagnosis in the teplizumab-treated group. Clinical benefits associated with reversed C-peptide decline improved...
Source: sciencemag.org